Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | 177Lu-NeoB |
| Trade Name | |
| Synonyms | lutetium neoB|177Lu-NeoBOMB1|Lutetium 177-NeoB|[177Lu]Lu-NeoB |
| Drug Descriptions |
177Lu-NeoB is a radioconjugate comprising the radionuclide Lutetium-177 linked to the GRPR-antagonist NeoB (NeoBOMB1), which delivers radiation to GRPR-expressing tumor cells, potentially resulting in inhibition of tumor growth (PMID: 37640941, PMID: 27609789). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C158734 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| 177Lu-NeoB | 177Lu-NeoB | 0 | 1 |
| 177Lu-NeoB + Capecitabine | 177Lu-NeoB Capecitabine | 0 | 0 |
| 177Lu-NeoB + Fulvestrant + Ribociclib | 177Lu-NeoB Fulvestrant Ribociclib | 0 | 1 |
| 177Lu-NeoB + Temozolomide | 177Lu-NeoB Temozolomide | 0 | 1 |